BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會

講師

Novel Targeted Technologies - SPARK

 

Novel Targeted Technologies: A Peptide Drug Conjugate for the Precision Therapy of Triple Negative Breast Cancer

Company Info

Name /Novel Targeted Technologies: A Peptide Drug Conjugate for the Precision Therapy of Triple Negative Breast Cancer

Address /Chief Investigator and the Leader of Breast Cancer Targeting- Drug Delivery Group at Sydney School of Pharmacy/ Co-Chair of NanoPharma at Sydney Nano Institute, The University of Sydney

Website /

Expecting startup year /2023

No. of team members /1 (Sole inventor) + my mentor (Prof Michael Wallach)

Presenter

Name /Pegah Varamini

Title /Dr

Email /pegah.varamini@sydney.edu.au

Telephone /(Work) +61 2 8627 0809

Fax /

Mobile /+61 411 730 278

Company Type

Pharmaceutical

About the Company

Dr Varamini is a University of Sydney Academic/Researcher. She designed a novel therapeutic technology to treat challenging types of cancer, e.g. triple-negative breast cancer (TNBC) with a patent filed (WO 2020/220085 A1). She is a part of the SPARK program being mentored towards translating her discovery from health research into new therapeutics that can be developed and brought into healthcare settings. This program also helps her to develop further strong IP for this technology. Her goal is to found TriOLife Pharmaceuticals aiming to improve the lives of patients suffering from TNBC and many other challenging types of cancer.

Brief Description of main products or services

A unique targeted peptide-drug conjugate (PDC) is designed by Dr Varamini as the Sole Inventor. This therapeutic technology offers a highly compelling value proposition in oncology:

  1. The technology can be used to treat challenging types of cancer, including TNBC and metastatic castrationresistant prostate cancer (mCRPC). Breast and prostate cancer are the first causes of cancer-related death in women and men, respectively, in Australia. About 15-20% of patients diagnosed with breast cancer are TNBC, and 50% of those diagnosed with prostate cancer will experience mCRPC throughout their lives, both of which have a poor prognosis.
  2. We have demonstrated that this new technology selectively targets cancer cells while sparing normal cells, leading to a high tolerance in animals. These properties are due to the extremely high stability of the novel targeting peptide and the careful selection of a stable linker. The maximum tolerated dose achieved was 7.2- fold higher than that of antibody-drug conjugate with the same payload. Furthermore, the construct has shown significant tumor growth inhibition in a murine TNBC model (up to 94.6% Tumor Growth Inhibition at BIO Asia-Taiwan 2021 Secretariat
    www.bioasiataiwan.com
    Email: register@taiwanbio.org.tw | Tel: +886-2-2783-6028 | Fax: +886-2-2783-6027
    Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571)
    a dose with no significant toxicity).
  3. Currently, antibody-drug conjugates (ADC)s are the leading therapeutic modality that enables the targeted delivery of highly potent cytotoxic payloads to tumors. Despite a high success rate, ADCs suffer from several challenges, including low tissue penetration that compromises the efficacy, high production costs and low product reproducibility. The designed PDC will overcome all those challenges. The cost of production of this novel PDC is 500-fold lower than that of the ADC with the same payload.

Contact Person

Name /Pegah Varamini

Email /pegah.varamini@sydney.edu.au

Phone /+61 2 8627 0809